Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.
Phase of Trial: Phase IV
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Graft-versus-host disease; Non-Hodgkin's lymphoma; Solid tumours
- Focus Therapeutic Use
- Sponsors Pharmacyclics Switzerland
- 06 Mar 2018 Planned End Date changed from 1 May 2020 to 2 Jul 2027.
- 06 Mar 2018 Planned primary completion date changed from 1 May 2020 to 2 Jul 2027.
- 29 Jul 2017 New trial record